<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T10:12:16Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/13959" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/13959</identifier><datestamp>2026-09-24T06:42:53Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Gabriele, Joseph</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Mishra, Ram</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="advisor" lang="en_US">Doering, Laurie</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author" lang="en_US">Lubarda, Jovana</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Neuroscience</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-06-18T17:05:42Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-06-18T17:05:42Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="created" lang="en_US">2014-02-04</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued" lang="en_US">2014-04</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">opendissertations/8791</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">9858</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other" lang="en_US">5060668</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/13959</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/18778</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">&lt;p>Parkinson’s disease (PD) is a complex neurodegenerative movement disorder involving protein misfolding, mitochondrial dysfunction, and oxidative stress. The current dissertation, motivated by a lack of valid biomarkers and sustainable therapies, examined the potential application of a novel target for therapeutics and diagnostics of PD — the multifunctional, heat-shock like protein Catecholamine-Regulated Protein 40 (CRP40). The goal of this program of research was to elucidate further the implications of CRP40 in PD using a variety of molecular biology, bioinformatics, and clinical approaches through integrative collaborations with academia, government, and industry partners to translate scientific findings into real world solutions. Chapters 2 and 3 explored the potential therapeutic use and structure-function relationships of CRP40 through elucidating the smallest functional piece of this protein that was six times smaller, and validating a negative control for these experiments (Heat-Shock Protein 47). These initiatives could eventually lead to a small drug that could cross the blood-brain barrier and be targeted to the specific brain regions affected in PD. Chapter 4 examined the potential mechanisms of CRP40, and suggested that this protein may protect neurons from oxidative stress, maintain energy levels, and mitochondrial homeostasis, with important future implications for a variety of disorders. Finally, Chapter 5 presented compelling evidence for the potential use of CRP40 as a valid biomarker for early detection of PD and monitoring of disease progression. Overall, findings suggest that CRP40 may be a critical target for future breakthroughs in the diagnosis and treatment of PD.&lt;/p></dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Science  (PhD)</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Catecholamine-regulated protein 40</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Parkinson’s disease</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">movement disorder</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">protein cloning</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">oxidative stress</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Diagnosis</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Biochemistry</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Medical Molecular Biology</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Nervous System Diseases</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Therapeutics</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Diagnosis</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">CATECHOLAMINE-REGULATED PROTEIN 40 IN PARKINSON’S DISEASE</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>